FY2027 Earnings Estimate for BSX Issued By Erste Group Bank

Boston Scientific Corporation (NYSE:BSX) – Investment analysts at Erste Group Bank dropped their FY2027 earnings per share (EPS) estimates for shares of Boston Scientific in a report released on Tuesday, March 24th. Erste Group Bank analyst H. Engel now anticipates that the medical equipment provider will post earnings per share of $3.91 for the year, down from their previous estimate of $3.92. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share.

BSX has been the topic of several other research reports. Morgan Stanley lowered their price objective on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Weiss Ratings lowered shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Truist Financial decreased their target price on shares of Boston Scientific from $95.00 to $92.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Robert W. Baird lowered their price target on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, TD Cowen dropped their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $106.27.

Boston Scientific Stock Up 2.3%

Boston Scientific stock opened at $69.70 on Thursday. The business’s 50-day moving average price is $78.22 and its 200 day moving average price is $91.25. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The firm has a market cap of $103.59 billion, a price-to-earnings ratio of 35.93, a price-to-earnings-growth ratio of 1.05 and a beta of 0.69. Boston Scientific has a 52 week low of $67.56 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the business posted $0.70 EPS. The company’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors have recently added to or reduced their stakes in the stock. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Steph & Co. purchased a new stake in Boston Scientific during the 3rd quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp increased its stake in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares in the last quarter. Financial Consulate Inc. acquired a new position in shares of Boston Scientific during the third quarter valued at approximately $25,000. Finally, Swiss RE Ltd. acquired a new position in shares of Boston Scientific during the fourth quarter valued at approximately $26,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 0.50% of the stock is owned by company insiders.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analyst support: TD Cowen highlighted strong early adoption of BSX’s Agent DCB and kept a Buy rating with a $100 price target, underpinning bullish investor sentiment on multi-year growth potential. Boston Scientific’s Agent DCB: Strong Early Adoption and Underappreciated Multiyear Growth Opportunity
• Positive Sentiment: Potential rating upgrade / turnaround view: A Seeking Alpha piece argues BSX is “under pressure but could see a shift in fortunes,” suggesting a rating upgrade could help sentiment if upcoming operational data improves. Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade)
• Positive Sentiment: Bullish “buy the dip” narratives: MarketBeat and other bullish write-ups view the recent pullback as an opportunity tied to pending trial results and long-term device adoption, supporting short-term buying interest. Why Boston Scientific’s Big Dip Could Be a Bigger Opportunity
• Neutral Sentiment: Industry note (unrelated company): Stratus Medical was named to Fortune’s Most Innovative Companies list — a positive for the RFA/chronic pain segment but not directly tied to BSX results. Investors may view it as a sector-level signal rather than company-specific news. Stratus Medical Recognized on Fortune’s America’s Most Innovative Companies List for 2026
• Negative Sentiment: Surge of securities-law firm notices and class-action filings allege misstatements around U.S. electrophysiology volumes; multiple firms (Bronstein, Faruqi, Levi & Korsinsky, Pomerantz, Rosen, Robbins, Bernstein Liebhard, etc.) are soliciting lead-plaintiff candidates and reminders about the May 4, 2026 deadline—heightening litigation risk and headline volatility for BSX. Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific Investors of Securities Class Action Deadline on May 4, 2026
• Negative Sentiment: Recent stock weakness and volatility: News outlets and Zacks noted BSX shares have recently traded down more sharply than the broader market, reflecting investor concern over guidance, electrophysiology volumes, and litigation headlines. Boston Scientific (BSX) Falls More Steeply Than Broader Market: What Investors Need to Know

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.